1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      JC virus-iLOV fluorescent strains enable the detection of early and late viral protein expression

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          JC virus (JCV) is highly prevalent in humans, and may cause progressive multifocal leukoencephalopathy (PML), JCV granule cell neuronopathy (JCV GCN), JCV encephalopathy (JCVE) and JCV meningitis (JCVM) in immunocompromised individuals. There is no treatment for JCV, and a growing number of multiple sclerosis patients treated with immunomodulatory medications have developed PML. Antiviral agents against JCV are therefore highly desirable but remain elusive, due to the difficulty of determining their effect in vitro. A JCV strain carrying a fluorescent protein gene would greatly simplify and accelerate the drug screening process. To achieve this goal, we selected the 366 bp improved Light, Oxygen or Voltage-sensing domain (iLOV) of plant phototropin gene and created two full-length JCV-iLOV constructs on the prototype JCV Mad1 backbone. The iLOV gene was inserted either before the early regulatory T gene (iLOV-T), or after the late Agno gene (iLOV-Agno). Both JCV iLOV strains were replication-competent in vitro and emitted a fluorescent signal detectable by confocal microscope, but JCV iLOV-T exhibited higher cellular and supernatant viral loads compared to JCV iLOV-Agno. JCV iLOV-T could also produce infectious pseudovirions. These data suggest that JCV iLOV constructs may become valuable tools for anti-JCV drug screening.

          Related collections

          Author and article information

          Journal
          8005839
          4621
          J Virol Methods
          J. Virol. Methods
          Journal of virological methods
          0166-0934
          1879-0984
          22 July 2015
          20 July 2015
          October 2015
          01 October 2016
          : 223
          : 25-29
          Affiliations
          [1 ]Division of Neuro Immunology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
          [2 ]Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
          [3 ]Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
          Author notes
          Corresponding author: Dr. Igor J. Koralnik, Chief, Division of Neuro Immunology, Beth Israel Deaconess Medical Center, CLS 1005, 330 Brookline Avenue, Boston, MA, 02215, Telephone #: (617) 735-4460, Fax #: (617) 735-4527, ikoralni@ 123456bidmc.harvard.edu
          Article
          PMC4554885 PMC4554885 4554885 nihpa709553
          10.1016/j.jviromet.2015.07.006
          4554885
          26205551
          0fa7a1a5-1a00-49f8-9017-d493fe59fa5f
          History
          Categories
          Article

          therapy,PML,drug screening,iLOV,JC virus
          therapy, PML, drug screening, iLOV, JC virus

          Comments

          Comment on this article